Dare Bioscience (NASDAQ:DARE) Stock Crosses Above 50 Day Moving Average – Time to Sell?

Shares of Dare Bioscience, Inc. (NASDAQ:DARE) passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $1.94 and traded as high as $2.0792. Dare Bioscience shares last traded at $1.95, with a volume of 73,715 shares traded.

Wall Street Analyst Weigh In

DARE has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Dare Bioscience in a research note on Tuesday, December 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Dare Bioscience in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Dare Bioscience has a consensus rating of “Hold” and a consensus price target of $10.00.

Dare Bioscience Trading Up 1.0%

The stock has a market cap of $27.87 million, a price-to-earnings ratio of -1.04 and a beta of 0.78. The business has a 50-day simple moving average of $1.94 and a two-hundred day simple moving average of $2.15. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.18 and a quick ratio of 1.18.

Dare Bioscience (NASDAQ:DARE) last released its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.05. The firm had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.01 million. Equities analysts forecast that Dare Bioscience, Inc. will post -0.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Dare Bioscience

A number of hedge funds have recently made changes to their positions in the stock. AMH Equity Ltd boosted its position in Dare Bioscience by 20.0% in the third quarter. AMH Equity Ltd now owns 232,373 shares of the biotechnology company’s stock valued at $488,000 after buying an additional 38,770 shares in the last quarter. Virtu Financial LLC bought a new stake in Dare Bioscience during the 3rd quarter worth $37,000. Finally, Raymond James Financial Inc. grew its position in Dare Bioscience by 810.6% during the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 13,650 shares during the last quarter. 6.70% of the stock is currently owned by institutional investors and hedge funds.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.